Severe resistant hypoglycemia in a patient with a pancreatic neuroendocrine tumor on sunitinib treatment

Athanasios Fountas, Stelios Tigas, Zoe Giotaki, Dimitrios Petrakis, George Pentheroudakis, Agathocles Tsatsoulis

Download PDF

OBJECTIVE: Sunitinib is a tyrosine kinase inhibitor used in the therapy of pancreatic neuroendocrine tumors (PNETs), metastatic renal cancer and gastrointestinal stromal tumors. We describe a patient with PNET who presented with severe hypoglycemia following sunitinib administration …